Skip to main content
SpringerLink
Log in

Oseltamivir

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Oseltamivir is the oral prodrug of GS4071, a selective inhibitor of influenza A and B viral neuraminidase. After absorption from the gastrointestinal tract oseltamivir is efficiently converted to GS4071, which is maintained at high and sustained concentrations in plasma.

  • ▴ Based on studies in rats and ferrets, GS4071 appears to be effectively distributed to all tissues, including major sites of infection in the upper and lower respiratory tracts.

  • ▴ Oral oseltamivir was an effective treatment in naturally occurring influenza when administered within 36 hours of symptom onset, reducing both the duration and severity of symptoms and the incidence of secondary complications in influenza-infected patients enrolled in 2 large placebo-controlled, double-blind trials.

  • ▴ Prophylactic oral administration of oseltamivir was effective in reducing the incidence of influenza illness according to pooled data from 2 large placebo-controlled, double-blind trials of healthy nonimmunised volunteers during periods of seasonal influenza activity.

  • ▴ The reported incidence of viral resistance to GS4071 was low in clinical isolates from oseltamivir treatment studies. All known GS4071 resistant genotypes are growth disadvantaged and display significantly reduced infectivity in animals.

  • ▴ Oseltamivir was well tolerated in human volunteers and patients in clinical trials. Treatment-related adverse events (primarily gastrointestinal) were mild and transient in nature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999 Apr 30; 48 (RR-4): 1–28

    Google Scholar 

  2. Nicholson KG. Managing influenza in primary care. London: Blackwell Science Ltd, 1999

    Google Scholar 

  3. Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998 Mar; 42: 640–6

    PubMed  CAS  Google Scholar 

  4. Sidwell RW, Huffman JH, Barnard DL, et al. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 1998 Feb; 37: 107–20

    Article  PubMed  CAS  Google Scholar 

  5. Hayden FG, Rollins BS. In vitro activity of the neuraminidase inhibitor GS4071 against influenza viruses [abstract no. 159]. Antiviral Res 1997 Apr; 34(2): A86

    Google Scholar 

  6. Roberts NA, Carr JC, Lambkin R, et al. Oral administration of the neuraminidase inhibitor prodrug GS4104 blocks influenza virus replication in ferrets [poster]. Annual Congress of the European Respiratory Society; 1998 Sep 19–23; Geneva, Switzerland

  7. Data on file, F. Hoffmann-La Roche, 1999

  8. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized, controlled trials for prevention and treatment. JAMA 1999 Oct 6; 282(13): 1240–6

    Article  PubMed  CAS  Google Scholar 

  9. Hayden FG, Fritz RS, Lobo M, et al. Effects of the oral neuraminidase inhibitor GS4104 on cytokine responses during experimental human influenza A virus infection [abstract]. Eur Respir J 1998 Sep; 12 Suppl. 28: 263s

    Google Scholar 

  10. Jennings LC, Robson RA, Jackson HC, et al. Oral GS4104 in experimental influenza B infection. Oral presentation, 11th International Congress of Virology; 1999 Aug 9–13; Sydney, Australia

  11. Treanor JJ, Betts RF, Kallas E, et al. Oral GS 4104prevents experimental infection of humans with influenza A (H1N1) virus [abstract]. Eur Respir J 1998 Sep; 12 Suppl. 28: 148s

    Google Scholar 

  12. Wood ND, Aitken M, Sharp S. Tolerability and pharmacokinetics of the influenza neuraminidase inhibitor Ro 64-0802 (GS4071) following oral administration of the prodrug Ro 64-0796 (GS4104) to healthy male volunteers [abstract no. A-123]. 37th ICAAC; 1997 Sep 28–Oct 1; Toronto, Canada

  13. Algranati NE, Massarella JW, Wood ND, et al. Pharmacokinetics and tolerability of the influenza neuraminidase inhibitor Ro 64-0802 following multiple dose oral administration of the prodrug Ro 64-0796 to healthy young and elderly subjects [abstract]. Eur Respir J 1998 Sep; 12 Suppl. 28: 149s–50s

    Google Scholar 

  14. Sidwell RW, Burger RA, Huffman JH, et al. Immunological effects of the orally administered neuraminidase inhibitor GS4104 in influenza virus-infected and uninfected mice [abstract no. H-72]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1998 Sep 24–27; San Diego

  15. Mendel DB, Sidwell RW. Influenza virus resistance to neuraminidase inhibitors. Drug Resist Update 1998; 1(3): 184–9

    Article  CAS  Google Scholar 

  16. Hayden FG. Influenza neuraminidase inhibitors [abstract/oral presentation]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1999 Sep 26–29; San Francisco

  17. Mendel_DB, Tai CY, Escarpe PA. In vitro selection and characterization of a human influenza virus with decreased susceptibility to GS 4071 [abstract]. Antiviral Res 1998 Mar; 37: A71

    Google Scholar 

  18. Gubareva LV, Robinson MJ, Bethell RC, et al. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Nue5Ac2en. J Virol 1997; 71: 3385–90

    PubMed  CAS  Google Scholar 

  19. Kim CU, Willard L, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997; 119(4): 681–90

    Article  PubMed  CAS  Google Scholar 

  20. Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999; 36 Suppl. 1: 1–11

    Article  PubMed  CAS  Google Scholar 

  21. He G, Massarella J, Schulz R, et al. The absolute bioavailability of the novel oral neuraminidase inhibitor R0 64-0796/GS4104 [poster]. American Association of Pharmaceutical Scientists, Southeast Regional Meeting; 1999 Jun 21; Durham (NC)

  22. He G, Massarella J, Schulz R, et al. The effect of food on the pharmacokinetics of the novel oral neuraminidase inhibitor RO 64-0796/GS4104 [poster]. American Association of Pharmaceutical Scientists, Southeast Regional Meeting; 1999 Jun 21; Durham (NC)

  23. Wiltshire HR, Muir J, Lambkin R, et al. Distribution of the influenza neuraminidase inhibitor GS4071 following oral administration of its prodrug GS4104 in ferrets [abstract/poster]. Meeting of the European Society for Clinical Virology; 1998 Aug 30–Sep 2; Hamburg, Germany

  24. Eisenberg EJ, Bidgood A, Cundy KC. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob Agents Chemother 1997 Sep; 41: 1949–52

    PubMed  CAS  Google Scholar 

  25. Cundy KC, Eisenberg G, Bidgood A. Enhanced delivery of the novel influenza neuraminidase inhibitor GS4071 to rat lung after oral administration of the prodrug GS4104 [abstract no. A-122]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1997 Sep 28–Oct 1; Toronto, Canada

  26. He G, Massarella J, Ward P. Summary of the clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite (Ro 64-0802). Clin Pharmacokinet 1999. In press

  27. Massarella JW, He GZ, Dorr A, et al. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (RO 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 1999. In press

  28. He G, Massarella J, Robson R, et al. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor Ro 64-0796 in subjects with renal impairment [poster]. 9th European Congress of Clinical Microbiology and Infectious Diseases; 1999 Mar 21–24; Berlin, Germany

  29. He G, Massarella M, Aitken A, et al. The safety and pharmacokinetics of the neuraminidase inhibitor Ro 64-0796 when administered concurrently with paracetamol [abstract]. Clin Microbiol Infect 1999 Mar; 5 Suppl. 3: 150

    Google Scholar 

  30. He G, Massarella J, Aitken M, et al. The pharmacokinetics and safety of the oral neuraminidase inhibitor RO 64-0796/GS4104 when administered concurrently with cimetidine or probenecid in healthy subjects [poster]. International Congress of Chemotherapy; 1999 July 4–7, Birmingham, England

  31. Treanor JJ, Vrooman PS, Hayden FG, et al. Efficacy of oral GS4104 in treating acute influenza [abstract no.LB-4]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego

  32. Aoki F, Osterhaus A, Rimmelzwaan G, et al. Oral GS4104 successfully reduces duration and severity of naturally acquired influenza [abstract/oral presentation]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24–27; San Diego

  33. Nicholson KG, Ward P, Kinnersley N, et al. Oral GS4104 in the treatment of influenza in adults is effective and reduces influenza-related complications and need for antibiotic treatment [abstract/poster]. 21 st International Congress of Chemotherapy; 1999 Jul 4–7; Birmingham, England

  34. Hayden FG, Atmar RL, Schilling M, et al. Safety and efficacy of a selective oral neuraminidase inhibitor (oseltamivir) to prevent influenza. N Engl J Med 1999. In press

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Anne Bardsley-Elliot & Stuart Noble

Authors
  1. Anne Bardsley-Elliot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stuart Noble
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne Bardsley-Elliot.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bardsley-Elliot, A., Noble, S. Oseltamivir. Drugs 58, 851–860 (1999). https://doi.org/10.2165/00003495-199958050-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958050-00007

Keywords

Search

Navigation